PT  - JOURNAL ARTICLE
AU  - Xavier Guitart
AU  - Gemma Navarro
AU  - Estefania Moreno
AU  - Hideaki Yano
AU  - Ning-Sheng Cai
AU  - Marta Sanchez
AU  - Sandeep Kumar-Barodia
AU  - Yamini Naidu
AU  - Josefa Mallol
AU  - Antoni Cortes
AU  - Carme Lluis
AU  - Enric I Canela
AU  - Vicent Casado
AU  - Peter J McCormick
AU  - Sergi Ferre
TI  - Functional Selectivity of Allosteric Interactions within GPCR oligomers: the Dopamine D1-D3 Receptor Heterotetramer
AID  - 10.1124/mol.114.093096
DP  - 2014 Aug 05
TA  - Molecular Pharmacology
PG  - mol.114.093096
4099  - http://molpharm.aspetjournals.org/content/early/2014/08/05/mol.114.093096.short
4100  - http://molpharm.aspetjournals.org/content/early/2014/08/05/mol.114.093096.full
AB  - The dopamine D1 receptor-D3 receptor (D1R-D3R) heteromer is being considered as a potential therapeutic target for neuropsychiatric disorders. Previous studies suggested that this heteromer could be involved in the ability of D3R agonists to potentiate locomotor activation induced by D1R agonists. It has also been postulated that its overexpression plays a role in L-dopa-induced dyskinesia and in drug addiction. However, little is known about its biochemical properties. By combining bioluminescence resonance energy transfer, bimolecular complementation techniques and cell signaling experiments in transfected cells, evidence was obtained for a tetrameric stoichiometry of the D1R-D3R heteromer, constituted by two interacting D1R and D3R homodimers coupled to Gs and GI proteins, respectively. Co-activation of both receptors led to the canonical negative interaction at the level of adenylyl cyclase signaling, to a strong recruitment of β-arrestin-1 and to a positive crosstalk of D1R and D3R agonists at the level of mitogen-activated protein kinase (MAPK) signaling. Furthermore, D1R or D3R antagonists counteracted β-arrestin-1 recruitment and MAPK activation induced by D3R and D1R agonists, respectively (cross-antagonism). Positive crosstalk and cross-antagonism at the MAPK level were counteracted by specific synthetic peptides with amino acid sequences corresponding to D1R transmembrane (TM) domains TM5 and TM6, which also selectively modified the quaternary structure of the D1R-D3R heteromer, as demonstrated by complementation of hemiproteins of YFP fused to D1R and D3R. These results demonstrate functional selectivity of allosteric modulations within the D1R-D3R heteromer, which can be involved with the reported behavioral synergism of D1R and D3R agonists.